Ozempic is not an SGLT2 inhibitor. It belongs to a completely different drug class called GLP-1 receptor agonists. The two classes lower blood sugar through distinct mechanisms, have different side effect profiles, and are sometimes even prescribed together. Understanding the difference matters because it affects what the medication does in your body and what to expect while taking it.
How Ozempic Actually Works
Ozempic’s active ingredient, semaglutide, is a lab-made version of a hormone your body naturally produces called GLP-1 (glucagon-like peptide-1). It binds to and activates the same receptor that native GLP-1 targets. When that receptor switches on, several things happen: your pancreas releases more insulin in response to food, your liver produces less sugar, your stomach empties more slowly, and your appetite decreases. That combination lowers blood sugar and typically leads to weight loss. In real-world use, patients on semaglutide lose an average of about 7.5% of their body weight.
Because semaglutide mimics a gut hormone, its most common side effects are gastrointestinal: nausea, vomiting, and diarrhea. Less common but more serious concerns include inflammation of the pancreas, gallbladder problems, and thyroid tumors observed in animal studies. About 8% of patients in one real-world Canadian study discontinued semaglutide due to side effects.
What SGLT2 Inhibitors Are
SGLT2 inhibitors work in the kidneys, not the gut. “SGLT2” stands for sodium-glucose cotransporter-2, a protein in your kidneys that normally reabsorbs sugar back into your bloodstream. These drugs block that protein, causing excess glucose to leave your body through urine. The FDA-approved SGLT2 inhibitors include canagliflozin (Invokana), dapagliflozin (Farxiga), and empagliflozin (Jardiance).
Because they flush sugar through the urinary tract, SGLT2 inhibitors carry a distinct set of risks: urinary tract infections, genital yeast infections, dehydration, low blood pressure, and in rare cases a serious condition called diabetic ketoacidosis. They also offer kidney-protective benefits, likely by reducing pressure inside the kidney’s filtering units, lowering blood pressure, and decreasing the workload on kidney tissue. That’s led to some SGLT2 inhibitors being approved specifically for chronic kidney disease and heart failure, beyond just blood sugar control.
Key Differences at a Glance
- Where they act: GLP-1 receptor agonists like Ozempic work primarily through gut hormones, the pancreas, and appetite centers in the brain. SGLT2 inhibitors work in the kidneys.
- How you take them: Ozempic is a once-weekly injection. SGLT2 inhibitors are daily pills.
- Weight loss: GLP-1 receptor agonists generally produce more weight loss than SGLT2 inhibitors. Semaglutide averages around 7.5% body weight loss, while SGLT2 inhibitors typically produce modest losses of 2 to 3%.
- Side effects: Ozempic’s main issues are nausea and other GI symptoms. SGLT2 inhibitors are more likely to cause urinary and genital infections.
Using Both Together
Because these two drug classes lower blood sugar through completely separate pathways, they can be prescribed at the same time. The SUSTAIN 9 clinical trial specifically tested adding semaglutide to patients already taking an SGLT2 inhibitor. Over 30 weeks, patients who added semaglutide saw their HbA1c (a measure of long-term blood sugar control) drop by an additional 1.42 percentage points compared to placebo, and they lost an extra 3.81 kg (about 8.4 pounds) on top of what the SGLT2 inhibitor alone achieved.
The combination was generally well tolerated. Gastrointestinal side effects were the most common issue, affecting 37% of patients on semaglutide versus 13% on placebo. Serious adverse events were similar between groups, at about 4 to 5%. Severe low blood sugar episodes were rare, occurring in only 2.7% of patients on semaglutide. The trial concluded that adding semaglutide is an effective option for people whose blood sugar isn’t adequately controlled on an SGLT2 inhibitor alone.
Why the Confusion Happens
Both GLP-1 receptor agonists and SGLT2 inhibitors are newer diabetes medications that emerged as alternatives to older drugs like metformin and sulfonylureas. They’re often discussed side by side in treatment guidelines, and both have shown cardiovascular benefits beyond blood sugar control. If your doctor has mentioned both classes or you’ve seen them compared online, it’s easy to blur the line between them. But they are pharmacologically unrelated, and knowing which class your medication falls into helps you understand why you’re experiencing certain side effects and what the drug is doing inside your body.